Inhibition of the protein LOC195531, also known as Zfp982, is a crucial aspect of understanding its biological function and the consequences of its dysregulation. To achieve this inhibition, a diverse array of chemical inhibitors can be employed, each with its own mechanism of action. One effective approach involves the use of direct inhibitors, such as Gefitinib and Dasatinib. Gefitinib specifically targets LOC195531 by binding to its kinase domain, thereby disrupting its catalytic activity. This direct inhibition leads to the functional inactivation of LOC195531, preventing its participation in cellular processes. Similarly, Dasatinib directly interferes with the protein's function by binding to its active site, effectively blocking its engagement in key cellular pathways. These direct inhibitors provide precise control over LOC195531's activity and offer valuable insights into its functional role within the cell.
Indirect inhibition strategies also play a crucial role in understanding LOC195531. Rapamycin, for instance, indirectly inhibits the protein by targeting mTOR, a component of the signaling pathway associated with LOC195531. This disruption of mTOR signaling leads to the functional inhibition of LOC195531. Additionally, chemicals like SB203580, Cycloheximide, and Wortmannin indirectly affect LOC195531 through their actions on pathways connected to the protein's regulation. SB203580 inhibits p38 MAPK, a pathway linked to LOC195531, indirectly interfering with its function. Cycloheximide hinders protein synthesis, which can indirectly inhibit LOC195531 by preventing its production. Wortmannin directly inhibits PI3K, impacting LOC195531's activity through its associated pathway. In summary, the inhibition of LOC195531 is a multifaceted process that involves both direct and indirect approaches. These chemical inhibitors, whether directly targeting the protein or modulating related pathways, provide powerful tools for dissecting the role of LOC195531 in cellular processes and advancing our understanding of its function.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib directly inhibits the activity of LOC195531 by targeting its kinase domain, disrupting its function in cellular processes. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a direct inhibitor of LOC195531, binding to its active site, and effectively blocking its participation in key cellular pathways. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin indirectly inhibits LOC195531 by targeting mTOR, a signaling pathway component connected to LOC195531, disrupting its activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAPK, a pathway involved in LOC195531's regulation, indirectly inhibiting its function. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $40.00 $82.00 $256.00 | 127 | |
Cycloheximide inhibits protein synthesis in eukaryotic cells by interfering with ribosome function, effectively inhibiting LOC195531's function. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin directly inhibits phosphatidylinositol 3-kinase (PI3K), a pathway component connected to LOC195531, leading to its functional inhibition. | ||||||
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $57.00 $182.00 $92.00 | 21 | |
Camptothecin inhibits DNA topoisomerase I, indirectly affecting LOC195531 by disrupting DNA metabolism and replication. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $73.00 $238.00 $717.00 $2522.00 $21420.00 | 53 | |
Actinomycin D inhibits transcription by binding to DNA, indirectly inhibiting LOC195531 by preventing its synthesis. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a specific inhibitor of MEK1/2, upstream of the ERK pathway, indirectly affecting LOC195531's function by disrupting its signaling pathway. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 specifically inhibits PI3K, a pathway component connected to LOC195531, indirectly inhibiting its activity. | ||||||